Biontech expands late-stage clinical oncology portfolio with initiation of further phase 2 trial with mrna-based individualized neoantigen specific immunotherapy in new cancer indication

Mainz, germany, october 19, 2023 (globe newswire) – biontech se (nasdaq: bntx, “biontech” or “the company”) today announced that the first patient has been treated in a phase 2 clinical trial evaluating the mrna-based individualized neoantigen-specific immunotherapy (inest) candidate autogene cevumeran (also known as bnt122, ro7198457) in resected pancreatic ductal adenocarcinoma (pdac). pdacs are solid tumors with a poor prognosis reflected in a 5-year overall survival rate of only 8-10%1 ,2, high recurrence rates3 and limited treatment options.
BNTX Ratings Summary
BNTX Quant Ranking